Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
307.20
+0.11 (0.04%)
Aug 14, 2025, 12:24 PM EDT
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
3.34
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
266.41B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Roche Holding AG News
- 3 days ago - Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters - Seeking Alpha
- 3 days ago - Swiss government to meet pharma firms to discuss US tariffs - Reuters
- 4 days ago - Swiss Government Engages Roche and Novartis on U.S. Tariff Impact - GuruFocus
- 10 days ago - Roche gets FDA clearance for respiratory test to detect viruses - Seeking Alpha
- 12 days ago - Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD) - GlobeNewsWire
- 12 days ago - Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD) - Business Wire
- 15 days ago - Trump's pharmaceutical tariffs could affect some drugmakers more than others - CNBC
- 16 days ago - U.S. and European Union trade deal could cost the pharma industry up to $19 billion - Fast Company